RxDoctor Payments Data

James Fitzpatrick, MD

Family Medicine · Mandeville, LANPI 1952359028

Payments from drug & device makers

$463in general payments, 2019–2025

Across 17 payments — averaging $27.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$187
  • Regeneron$138
  • Sumitomo Pharma America, Inc.$43
  • Amgen$30
  • Abbott$25
  • Philips North America LLC$24
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$463 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$51,240
Medicare patients
126
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin129$119,124
OzempicSemaglutide55$67,178
EliquisApixaban77$60,173
TrulicityDulaglutide23$37,189
JanuviaSitagliptin Phosphate26$29,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$29,680
FarxigaDapagliflozin Propanediol11$15,947
XareltoRivaroxaban25$15,610
MyrbetriqMirabegron24$12,443
LinzessLinaclotide13$12,118
Spiriva RespimatTiotropium Bromide12$10,284
Tresiba Flextouch U-100Insulin Degludec11$9,103
SymbicortBudesonide/Formoterol Fumarate22$7,405
Rosuvastatin Calcium617$7,071
Repatha SureclickEvolocumab12$6,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$67,17855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Mandeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →